triple negative metaplastic breast cancer

Release time ：Dec-22,2024

Triple-negative metaplastic breast cancer represents a rare and formidable variant of breast cancer, characterized by complex treatment challenges and a generally unfavorable prognosis.

The diagnosis hinges on the absence of three key receptors on tumor cell surfaces: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Consequently, standard hormonal therapies and HER2-targeted treatments are ineffective for this breast cancer type. Moreover, the diverse biological behaviors and heterogeneity of triple-negative metaplastic breast cancer lead to significant variations in clinical presentation and treatment responses. While some patients may respond well to chemotherapy, others may be at a higher risk of recurrence and have a lower survival rate. Additionally, the subtypes of triple-negative metaplastic breast cancer, such as basal-like and immunomodulatory types, exhibit different treatment approaches and prognoses.

For patients afflicted with triple-negative metaplastic breast cancer, vigilant monitoring of disease progression and regular imaging and tumor marker assessments are advised. Treatment should adhere to personalized principles, tailoring therapeutic strategies to the patient's specific condition, physical status, and treatment responsiveness. Patients are also encouraged to maintain a positive mindset and actively engage in treatment to enhance therapeutic outcomes and overall quality of life. Timely medical consultation and professional advice are essential for addressing any concerns or symptoms that arise.